0.00Open0.00Pre Close0 Volume0 Open Interest14.00Strike Price0.00Turnover126.66%IV-40.00%PremiumJan 17, 2025Expiry Date4.00Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8154Delta0.0855Gamma2.35Leverage Ratio-0.0172Theta-0.0060Rho-1.92Eff Leverage0.0067Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet